Koers Oncolytics Biotech Inc. Toronto S.E.
Aandelen
CA6823101077
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 750K 546K 510K | Omzet 2025 * | 5,72 mln. 4,17 mln. 3,89 mln. | Marktkapitalisatie | 116 mln. 84,56 mln. 78,98 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -35 mln. -25,48 mln. -23,8 mln. | Nettowinst (verlies) 2025 * | -40 mln. -29,12 mln. -27,2 mln. | EV/omzet 2024 * | 155 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 20,3 x |
K/w-verhouding 2024 * |
-3,51
x | K/w-verhouding 2025 * |
-3,57
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,1% |
Recentste transcriptie over Oncolytics Biotech Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Matthew Coffey
CEO | Chief Executive Officer | - | 11-05-11 |
Kirk Look
DFI | Director of Finance/CFO | - | 01-04-03 |
Thomas Heineman
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Rigby
BRD | Director/Board Member | 56 | 07-09-22 |
Patricia Andrews
BRD | Director/Board Member | 66 | 09/01 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 08-06-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,67% | 42,19 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,63 mld. | |
-21,66% | 18,2 mld. | |
+29,96% | 12,01 mld. | |
-1,57% | 11,76 mld. | |
+16,03% | 10,4 mld. | |
-4,80% | 9,94 mld. |